对抗药性症中的布里瓦拉的定量EEG分析:一个药物-EEG研究
Lorenzo Ricci1, Mario Tombini2, Ersilia Savastano3
1Department of Medicine and Surgery, Research Unit of Neurology, Neurobiology, Neurophysiology, University Campus Bio-Medico di Roma, Rome, Italy; Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Via Alvaro del Portillo, 200, 00128 Rome, Italy; Medical Statistic and Molecular Epidemiology Unit, University Campus Bio-Medico di Roma, Rome, Italy.
概括
布里瓦拉 (BRV) 没有改变EEG功率,但在患者中正常化了大脑连接. 这表明了有利的安全性概况和潜在的机制来减少焦点发作.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 的研究研究.
背景情况:
- 布里瓦拉 (BRV) 是一种治疗焦点的抗发作药物 (ASM).
- 它对静止状态EEG活动和连接性的影响在很大程度上是未知的.
- 了解这些影响对于评估其有效性和安全性概况至关重要.
研究的目的:
- 评估BRV疗法诱导的成年药物耐药性症 (PwE) 的定量EEG变化.
- 为了比较用BRV治疗的PWE与健康对照 (HC) 的EEG活动和连接性.
- 调查BRV对EEG参数与治疗反应相关的影响.
主要方法:
- 一个纵向的,回顾性药物-EEG研究,涉及23个PWE和25个HC.
- EEG参数,包括连接的相锁定值 (PLV),在基线和BRV治疗三个月后进行评估.
- 临床结果根据发作减少被分为响应者 (RES) 和非响应者 (N-RES).
主要成果:
- BRV治疗没有改变不同频段的EEG功率频谱密度.
- 普华永道在所有频段的PLV连接率低于HC.
- 药物响应者 (RES) 在BRV后显示了theta PLV连接性增加,使HC的差异正常化.
结论:
- BRV不会改变EEG功率谱,支持其有利的神经精神病学副作用.
- BRV疗法使PWE和HC之间的EEG连接差异正常化.
- 定量EEG分析为ASM疗效,机制和的副作用提供了宝贵的见解.
相关概念视频
01:24Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287